Evidence map›Paper›PMID 38094161›Full record

ArticleEClinicalMedicine2023

Deep learning signature based on multiphase enhanced CT for bladder cancer recurrence prediction: a multi-center study.

Hexiang Wang, Meng Zhang, Jianguo Miao, Feng Hou, Yunqing Chen, Yonghua Huang, Lei Yang, Shifeng Yang, Chencui Huang, Yancheng Song and 1 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hexiang WangDepartment of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Meng ZhangDepartment of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Jianguo MiaoCollege of Computer Science and Technology, Qingdao University, Qingdao, 266071, Shandong, China.
Feng HouDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Yunqing ChenDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Yonghua HuangDepartment of Radiology, The Puyang Oilfield General Hospital, Puyang, 457001, Henan, China.
Lei YangDepartment of Radiology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, 266042, China.
Shifeng YangDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250000, Shandong, China.
Chencui HuangDepartment of Research Collaboration, R&D Center, Beijing Deepwise & League of PHD Technology Co., Ltd., Beijing 100080, China.
Yancheng SongDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Haitao NiuDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate stratification of recurrence risk for bladder cancer (BCa) is essential for precise individualized therapy. This study aimed to develop and validate a model for predicting the risk of recurrence in BCa patients postoperatively using 3-phase enhanced CT images. Methods: We retrospectively enrolled 874 BCa patients across four centers between January 2006 and December 2021. Patients from one center were used as training set, while the remaining patients went into the validation set. We trained a deep learning (DL) model based on convolutional neural networks using 3-phase enhanced CT images. The resulting prediction scores were entered into Cox regression analysis to obtain DL scores and construct a DL signature. DL scores and clinical features were then used as deep learning radioclinical signature. The predictive performance of DL signature was assessed according to concordance index and area under curve compared with deep learning radioclinical signature, clinical model and a widely accepted staging grading system. Recurrence-free survival (RFS) and overall survival (OS) were also predicted in order to further assess survival benefits. Findings: DL signature showed strong power for predicting recurrence (concordance index, 0.869; area under curve, 0.889) in validation set, outperforming other models and system. In addition, we divided RFS and OS into high and low risk groups by selecting appropriate cutoff values for DL signature, and calculated cumulative recurrence risk rates for both groups. Interpretation: Our proposed DL signature shows promising potential as clinical aid for predicting postoperative recurrence risk in BCa and for stratifying the risk of RFS and OS, which can be applied to guide personalized precision therapy. Funding: There are no sources of funding for this manuscript.

Indexed as

Bladder cancerDeep learningPrognosisRecurrenceRisk stratification

Identifiers

PMID38094161
PMCPMC10716002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.